Consumer Product Testing Co.

EST. 1975

FINAL REPORT

CLIENT: Optigenex, Inc.
750 Lexington Ave., 6th Floor
New York, New York 10022

ATTENTION: Jerry Wachs, M.D.

TEST: Repeated Insult Patch Test
Protocol No.: 1.01

TEST MATERIAL: Night Cream Lot# 1638

EXPERIMENT REFERENCE NUMBER: C05-0695.02

Richard R. Eisenberg, M.D.
Board Certified Dermatologist

Joy Frank, R.N.
Executive Vice President, Clinical Evaluations

70 New Dutch Lane • Fairfield, New Jersey 07004-2514 • (973) 808-7111 • Fax (973) 808-7234

Consumer Product Testing Co.
EST. 1975

QUALITY ASSURANCE UNIT STATEMENT

Study No.: C05-0695.02

The objective of the Quality Assurance Unit (QAU) is to monitor the conduct and reporting of clinical laboratory studies. These studies have been performed with adherence to the applicable ICH Guideline E6 for Good Clinical Practice and requirements provided for in 21 CFR parts 50 and 56 and in accordance to standard operating procedures and applicable protocols. The QAU maintains copies of study protocols and standard operating procedures and has inspected this study. All data pertinent to this study will be stored in the Consumer Product Testing Company archive, unless specified otherwise, in writing by the Sponsor.

Quality Assurance personnel involved:

Gaynel Hettenbach 10/12/05
Quality Assurance Date

The representative signature of the Quality Assurance Unit signifies that this study has been performed in accordance with standard operating procedures and study protocol as well as government regulations regarding such procedures and protocols.

Objective: To determine by repetitive epidermal contact the potential of a test material to induce primary or cumulative irritation and/or allergic contact sensitization.

Participants: Fifty-seven (57) qualified subjects, male and female, ranging in age from 17 to 68 years, were selected for this evaluation. Fifty-four (54) subjects completed this study. The remaining subjects discontinued their participation for various reasons, none of which were related to the application of the test material.

Inclusion Criteria:

a. Male and female subjects, age 16[a] and over.
b. Absence of any visible skin disease which might be confused with a skin reaction from the test material.
c. Prohibition of use of topical or systemic steroids and/or antihistamines for at least seven days prior to study initiation.
d. Completion of a Medical History form and the understanding and signing of an Informed Consent form.
e. Considered reliable and capable of following directions.

Exclusion Criteria:

a. Ill health.
b. Under a doctor's care or taking medication(s) which could influence the outcome of the study.
c. Females who are pregnant or nursing.
d. A history of adverse reactions to cosmetics or other personal care products.

Test Material: Night Cream Lot# 1638

Study Schedule:

Panel #	Initiation Date	Completion Date
20050416	August 29, 2005	October 6, 2005

[a]With parental or guardian consent

Methodology:

The upper back between the scapulae served as the treatment area. Approximately 0.2 g of the test material, or an amount sufficient to cover the contact surface, was applied to the 3/4" x 3/4" absorbent pad portion of an adhesive dressing*. This was then applied to the appropriate treatment site to form an occlusive patch.

Induction Phase:

Patches were applied three (3) times per week (e.g., Monday, Wednesday, and Friday) for a total of nine (9) applications. The site was marked to ensure the continuity of patch application. Following supervised removal and scoring of the first Induction patch, participants were instructed to remove all subsequent Induction patches at home, twenty-four hours after application. The evaluation of this site was made again just prior to re-application. If a participant was unable to report for an assigned test day, one (1) makeup day was permitted. This day was added to the Induction period. It was noted that due to a holiday weekend which occurred during the Induction Phase, subjects who required a makeup day experienced a delay between applications.

With the exception of the first supervised Induction Patch reading, if any test site exhibited a moderate (2-level) reaction during the Induction Phase, application was moved to an adjacent area. Applications are discontinued for the remainder of this test phase, if a moderate (2-level) reaction was observed on this new test site. Applications would also be discontinued if marked (3-level) or severe (4-level) reactivity was noted.

Rest periods consisted of twenty-four hours following each Tuesday and Thursday removal, and forty-eight hours following each Saturday removal.

Challenge Phase:

Approximately two (2) weeks after the final Induction patch application, a Challenge patch was applied to a virgin test site adjacent to the original Induction patch site, following the same procedure described for Induction. The patch was removed and the site scored at the clinic twenty-four and seventy-two hours post-application.

*Manufactured by TruMed Technologies, Inc., Burnsville, MN

Evaluation Key:

0 = No visible skin reaction
+ = Barely perceptible or spotty erythema
1 = Mild erythema covering most of the test site
2 = Moderate erythema, possible presence of mild edema
3 = Marked erythema, possible edema
4 = Severe erythema, possible edema, vesiculation, bullae and/or ulceration

Results:

The results of each participant are appended (Table 1).

Observations remained negative throughout the test interval.

Summary:

Under the conditions of this study, test material, Night Cream Lot# 1638, did not indicate a potential for dermal irritation or allergic contact sensitization.

Table 1
Panel #20050416

Individual Results

Night Cream Lot# 1638

Subject Number	24*hr	Induction Phase 1	2	3	4	5	6	7	8	9	Virgin Challenge Site 24*hr	72 hr
1	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0
12	----------DID NOT COMPLETE STUDY----------											
13	0	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0	0
15	----------DID NOT COMPLETE STUDY----------											
16	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0	0

24* = Supervised removal of 1st Induction and Challenge Patch

Table 1
(continued)
Panel #20050416

Individual Results

Night Cream Lot# 1638

Subject Number	24*hr	Induction Phase 1	2	3	4	5	6	7	8	9	Virgin Challenge Site 24*hr	72 hr
30	0	0	0	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0	0
48	----------DID NOT COMPLETE STUDY----------											
49	0	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0	0	0	0

24* = Supervised removal of 1st Induction and Challenge Patch

Table 2
Panel #20050416

Subject Data

Subject Number	Initials	Age	Sex
1	BO	44	F
2	DH	35	F
3	DS	46	F
4	DC	59	F
5	CC	59	M
6	JD	65	F
7	LJ	64	F
8	KM	47	F
9	LS	38	F
10	RG	54	M
11	ML	57	F
12	SB	24	F
13	EH	47	F
14	AT	32	M
15	ER	54	F
16	AR	58	M
17	MR	55	F
18	JF	28	M
19	RG	32	M
20	EA	58	F
21	MG	59	M
22	CG	38	F
23	SC	48	F
24	LP	33	F
25	GB	50	F
26	IO	53	F
27	ST	48	M
28	PS	46	F
29	ZS	63	F

Table 2
(continued)
Panel #20050416

Subject Data

Subject Number	Initials	Age	Sex
30	RL	44	F
31	JD	45	F
32	DD	17	M
33	DE	50	F
34	RE	52	M
35	EG	62	F
36	CC	68	F
37	IR	42	M
38	LD	41	F
39	KE	48	F
40	DP	47	M
41	CP	47	F
42	DR	59	F
43	AD	55	F
44	RQ	23	F
45	SS	34	F
46	JD	40	F
47	NH	47	F
48	NP	38	M
49	EG	54	F
50	NG	59	F
51	MF	58	F
52	RG	38	F
53	MH	27	F
54	EV	56	F
55	FA	56	M
56	JA	25	F
57	JA	42	M